OncoOne
- Company typePrivate
- Founded2018
- HeadquartersKlosterneuburg, Austria
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
OncoOne firmographics
Firmographics- Name
- OncoOne
- Website
- https://oncoone.com
- Company type
- Private
- Founded year
- 2018
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
OncoOne industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where OncoOne is headquartered
LocationHeadquarters
- HQ city
- Klosterneuburg
- HQ country
- Austria
- HQ region
- Europe
Markets served
OncoOne business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
OncoOne product offering
Product offeringCore offering
OncoOne is a biotech start-up dedicated to developing innovative therapeutics, focused on oncology drug discovery and development. The company is engaged in research and development activities to create novel biologic therapeutics for cancer treatment, leveraging biotechnology expertise to advance candidates toward clinical use.
Differentiator
Problem solved
Functional benefit
Products and services
- Innovative Cancer Therapeutics Pipeline
Companies that use OncoOne
Customer profileIdeal customer profiles2 records
OncoOne technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
OncoOne partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights2 records
OncoOne competitors and assessment
Company assessmentDirect peers
- Hookipa Pharma: Austrian clinical-stage biotech developing immuno-oncology and infectious disease therapeutics using an arenavirus-based platform. Closely comparable to OncoOne in geography, stage, and oncology-focused innovator drug development.
- Immatics: Clinical-stage biopharmaceutical company focused on immuno-oncology, developing TCR-based therapeutics and adoptive cell therapies. Directly comparable in oncology therapeutic modality and biotech-discovery positioning.
- Celyad Oncology: Belgian clinical-stage biotech developing CAR-T and RNA-based oncology therapeutics. Comparable as an EU-based oncology biotech developing innovative cell and gene therapy approaches for cancer.
- Adaptimmune: Clinical-stage biotech developing SPEAR T-cell receptor therapies for solid tumors. Comparable as an oncology-focused innovator biotech with platform-based therapeutic discovery.
- Innate Pharma: French clinical-stage biotech developing immuno-oncology therapeutics using antibody and innate immune system approaches. Comparable as a European oncology innovator biotech at a similar scientific stage.
Regional players
- Apeiron Biologics: Austrian biotech developing immuno-oncology therapeutics, including APN401 and related assets. Comparable as an Austria-headquartered oncology biotech with a similar innovator-drug posture.
Broad incumbents
- PharmaMar: Established European oncology company commercializing marine-derived anticancer therapeutics (e.g., Yondelis, Zepzelca). Comparable as a European oncology therapeutics developer, though larger and revenue-generating.
Emerging players
- Polaris Pharmaceuticals: Emerging oncology biotech developing novel small-molecule and biologic therapeutics for cancer. Comparable as an early-stage oncology therapeutics developer with a similar discovery-stage profile.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
OncoOne social profiles
Digital presenceOncoOne financial estimates
Financial estimateRevenue estimate
Valuation estimate
OncoOne leadership team
Management profileNumber of profiles
OncoOne funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OncoOne M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OncoOne
What does OncoOne do?
OncoOne is a biotech start-up dedicated to developing innovative therapeutics, focused on oncology drug discovery and development. The company is engaged in research and development activities to create novel biologic therapeutics for cancer treatment, leveraging biotechnology expertise to advance candidates toward clinical use.
When was OncoOne founded?
OncoOne was founded in 2018. It employs 1 to 10 people.
Where is OncoOne based?
OncoOne is headquartered in Klosterneuburg, Austria, in the Europe region.
Who are OncoOne's main competitors?
Direct peers on record are Hookipa Pharma, Immatics, Celyad Oncology, Adaptimmune and Innate Pharma. Apeiron Biologics is listed as a regional player. PharmaMar is listed as a broad incumbent. Polaris Pharmaceuticals is listed as an emerging player.
Does OncoOne have an API?
No public API is recorded for OncoOne.
What industry is OncoOne in?
OncoOne's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.